BLUE logo

BLUE bluebird bio, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$4.97
+0.00 (+0.00%)

bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; …

Market Cap: $48.67Mwww.genetixbiotx.com

Price

No data yet.

Social Signal Score

37
5d
—
30d
—
60d
37
3 mentions
—
90d
37
3 mentions
—
news: 3

Analyst Ratings

37 analysts
Holdconsensus
Strong Buy 0Buy 14Hold 19Sell 4Strong Sell 0
Avg price target$13.69+175.5%
Low $5Median $12.5High $25
Current Consensus

Revenue

$38.71M+683.64%
$62.0K$66.34M$132.61M$198.89M
Jun 2015Mar 2025

Analyst Estimates

FY2025
$-14.47
$-29.64–$-5.28
3 analysts
FY2026
$-8.56
$-8.56–$-8.56
1 analysts
FY2027
$-6.86
$-6.86–$-6.86
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Andrew Obenshain
Sector
Healthcare
Industry
Biotechnology
Employees
248
Beta
0.36
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-23.54
www.genetixbiotx.com